Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 20:42:136.
doi: 10.11604/pamj.2022.42.136.32041. eCollection 2022.

Performance of Xpert HIV-1 viral load test in Senegal: a country of high circulation of CRF02_AG

Affiliations

Performance of Xpert HIV-1 viral load test in Senegal: a country of high circulation of CRF02_AG

Pauline Yacine Sène et al. Pan Afr Med J. .

Abstract

Introduction: the introduction of the point-of-care in HIV-1 viral load quantification appears to be a complementary strategy to the existing conventional system of the acceleration plan for the achievement of the three 90s in Senegal. The objective of this study was to evaluate the performance of the Xpert® HIV-1 viral load in the context of circulation of non-B, non-C subtypes.

Methods: two hundred samples, were tested on Xpert® HIV-1 Viral Load using 1 ml of plasma in comparison to 600 μl on Abbott Real-time HIV-1 assay. The difference between viral load values was considered significant for Dlog <0.5 log copies/ml.

Results: a good correlation (r=0.985) was noted and confirmed using passing-bablok regression (slope 1.048; 95% CI: 1.036 to 1.069) for 188 samples with samples. A mean difference of 0.0075 log10 copies/ml for a 95% confidence interval (CI) of 0.002 log10 copies/ml to 0.013 log10 copies/ml was obtained. Sensitivity and specificity were respectively 93.6% and 93.5% at the threshold of 1.6 log10 copies/ml and 100% and 99% at the threshold of 3.0 log10 copies/ml.

Conclusion: these results show that Xpert® HIV-1 Viral Load has excellent performance. In Senegal, and can be used for HIV viral load monitoring.

Keywords: CRF02_AG; HIV-1; Senegal; plasma; point of care system; viral load.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Figure 1
Figure 1
passing-Bablok regression for Xpert® HIV-1 viral load and the Abbott Real-time HIV-1 assay
Figure 2
Figure 2
bland-Altman plot comparing Xpert® HIV-1 viral load against the Abbott Real-time HIV-1 assay
Figure 3
Figure 3
phylogenetic tree of samples with D-log< 0.5 log copies/ml

References

    1. ONUSIDA. 90-9090 treatment target. Accessed June 24, 2022.
    1. United Nations Programme on HIV and AIDS 2025. AIDS target. Accessed October 11, 2021.
    1. Liégeois F, Eymard-Duvernay S, Boyer S, Maradan G, Kouanfack C, Domyeum J, et al. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM) HIV Med. 2019 Jan;20(1):38–46. - PubMed
    1. Desclaux A, Ciss M, Taverne B, Sow PS, Egrot M, Faye MA, et al. Access to antiretroviral drugs and AIDS management in Senegal. AIDS. 2003 Jul;17(Suppl 3):S95–101. - PubMed
    1. Ministère de la Santé et de la Prévention. Rapport annuel DLSI 2017. 2017.